In one retrospective real-life study, switching from anti-IL-5 to anti-IL-5Rα therapy due to inadequate treatment response (lack of reduction in exacerbation rate or OCS dosage), persistent impairment of lung function tests or adverse effects, was associated with significantly improved FEV1, asthma control and OCS reduction [64]. This evidence concerns the gene IL5RA and asthma.